Pisanti Simona, Malfitano Anna Maria, Grimaldi Claudia, Santoro Antonietta, Gazzerro Patrizia, Laezza Chiara, Bifulco Maurizio
Department of Pharmaceutical Sciences, University of Salerno, Italy.
Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):117-31. doi: 10.1016/j.beem.2009.02.001.
Cannabinoids (the active components of Cannabis sativa) and their derivatives have received renewed interest in recent years due to their diverse pharmacological activities. In particular, cannabinoids offer potential applications as anti-tumour drugs, based on the ability of some members of this class of compounds to limit cell proliferation and to induce tumour-selective cell death. Although synthetic cannabinoids may have pro-tumour effects in vivo due to their immunosuppressive properties, predominantly inhibitory effects on tumour growth and migration, angiogenesis, metastasis, and also inflammation have been described. Emerging evidence suggests that agonists of cannabinoid receptors expressed by tumour cells may offer a novel strategy to treat cancer. In this chapter we review the more recent results generating interest in the field of cannabinoids and cancer, and provide novel suggestions for the development, exploration and use of cannabinoid agonists for cancer therapy, not only as palliative but also as curative drugs.
大麻素(大麻的活性成分)及其衍生物近年来因其多样的药理活性而重新受到关注。特别是,基于这类化合物中的一些成员具有限制细胞增殖和诱导肿瘤选择性细胞死亡的能力,大麻素作为抗肿瘤药物具有潜在应用价值。尽管合成大麻素由于其免疫抑制特性在体内可能具有促肿瘤作用,但主要对肿瘤生长、迁移、血管生成、转移以及炎症的抑制作用已被描述。新出现的证据表明,肿瘤细胞表达的大麻素受体激动剂可能为治疗癌症提供一种新策略。在本章中,我们回顾了在大麻素与癌症领域引发关注的最新研究结果,并为开发、探索和使用大麻素激动剂进行癌症治疗提供新建议,不仅作为姑息性药物,也作为治愈性药物。